Stoke Therapeutics published its annual report on Form 10-K for FY 2025. Revenue rose more than tripled to USD 184.42 million, driven mainly by USD 150.8 million tied to an IP license performance obligation and USD 17.5 million for global development activities under the Biogen collaboration. Net loss narrowed to USD 6.89 million, while R&D expenses increased 54.8% to USD 137.92 million, primarily due to higher spending on the zorevunersen program and increased personnel-related costs. SG&A expenses increased 37.5% to USD 67.09 million, reflecting higher personnel-related costs and third-party services to support commercialization and other corporate activities. Cash, cash equivalents and marketable securities totaled USD 390.9 million, and management said it expects this to fund operations into 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-108362), on March 16, 2026, and is solely responsible for the information contained therein.